Genentech Plans Herceptin Filing In Adjuvant Setting; Survival Benefit Shown
Executive Summary
Genentech is preparing to submit a supplemental BLA for Herceptin for the adjuvant treatment of early-stage HER-2 positive breast cancer based on positive interim results from Phase III studies
You may also be interested in...
Herceptin Adjuvant Approval Has 65% Higher Price Than Metastatic Therapy
The average cost per one-year course of Herceptin (trastuzumab) for adjuvant HER2-positive breast cancer will be $38,007, or 65% more than a course for the biologic's metastatic breast cancer indication
Herceptin Adjuvant Approval Has 65% Higher Price Than Metastatic Therapy
The average cost per one-year course of Herceptin (trastuzumab) for adjuvant HER2-positive breast cancer will be $38,007, or 65% more than a course for the biologic's metastatic breast cancer indication
Tykerb Effective In Herceptin Failures; CNS Relapse Rate, CV Safety Touted
GlaxoSmithKline's Tykerb (lapatinib) should replace Genentech's Herceptin (trastuzumab) as the standard of care for trastuzumab-refractory breast cancer patients, GSK Senior VP-Oncology Medicine Development Center Paolo Paoletti said June 3